ID: ALA5280482

Max Phase: Preclinical

Molecular Formula: C26H33NO

Molecular Weight: 375.56

Representations

Canonical SMILES:  CCCCCCCCC(=O)N1CCC(C2c3ccccc3-c3ccccc32)C1

Standard InChI:  InChI=1S/C26H33NO/c1-2-3-4-5-6-7-16-25(28)27-18-17-20(19-27)26-23-14-10-8-12-21(23)22-13-9-11-15-24(22)26/h8-15,20,26H,2-7,16-19H2,1H3

Standard InChI Key:  UOYCHYAYGKUTNB-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 375.56

Molecular Weight (Monoisotopic): 375.2562

AlogP: 6.40

#Rotatable Bonds: 8

Polar Surface Area: 20.31

Molecular Species: NEUTRAL

HBA: 1

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 2

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa:

CX LogP: 6.23

CX LogD: 6.23

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.49

Np Likeness Score: -0.36

References

1. Matviiuk T, Madacki J, Mori G, Orena BS, Menendez C, Kysil A, André-Barrès C, Rodriguez F, Korduláková J, Mallet-Ladeira S, Voitenko Z, Pasca MR, Lherbet C, Baltas M..  (2016)  Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.,  123  [PMID:27490025] [10.1016/j.ejmech.2016.07.028]

Source

Source(1):

• Scientific Literature